Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Bullock group was delighted to welcome the FOP Friends charity and patient families to the CMD in October. FOP (fibrodysplasia ossificans progressiva) is a congenital syndrome of extraskeletal bone formation caused by a gain of function mutation in the ACVR1/ALK2 protein kinase. Families were given a lab tour and updated on the latest research news, including progress of the “STOPFOP” clinical trial developed by the Bullock group and collaborators.

FOP Friends visit